TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04064684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Enrolled patients will be treated with Pulmicort Respules® (Budesonide inhalation suspension), at a dose of 0.5 mg, nebulized twice daily through the mechanical ventilator. The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulizer
Description: The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nebulizer
Description: The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit.
Study: NCT04688567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-driven iCBT
Description: 1) Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment by the time of the randomization call. The participant can choose which of the available treatment programs (targeting anxiety, worry, stress, sleep disorders or depression) they want to undergo, how many modules in the treatment program they want to complete and in what order, for how many weeks they want to complete the treatment as well as how much telephone contact and how much written contact they want to have with their therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized iCBT (TAU)
Description: 2) Patients who are randomized to the control condition (standardized iCBT) undergo the usual iCBT program available for anxiety disorders for 8 weeks. The psychologist provide weekly feedback on the patient's exercises and interact with the patient via secure encrypted messages in the treatment program. A follow-up telephone call takes place at the middle of treatment and at the end of the treatment.
Study: NCT04069767

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICoreDIST
Description: The intervention consists of exercises that demand enhancement of dynamic trunk stability and functional movements, combined with the following:~1. Optimised alignment and adaptation to the base of support and often using an unstable reference point for the trunk (therapeutic ball) or the distal body parts.~2. Enhanced somatosensory integration of hands, feet and face, including reduced influence of vision to enhance somatosensory integration.~3. Proximal stability prior to selective task-oriented movement of limbs, head, eyes.~4. Inclusion of dual tasks (motor/motor and motor/cognitive) in exercises and activities such as walking indoors, out-doors and climbing stairs.~5. Specific hands-on interactions or other adaptations to optimise alignment and neuromuscular recruitment.~6. Exercises combining core activation and moderate increase in heart rate: in lying, sitting, standing and walking.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: According to national guidelines for stroke care, every patient in Norway will receive in-patient rehabilitation, home-based and out-patient based physiotherapy.
Study: NCT03731416

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: GBR by xenograft and autogenous bone
Description: Ridge augmentation by native collagen membrane and mix of anorganic bovine bone derived mineral with particulated autogenous bone chips (ratio 1:1).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GBR by xenograft and autogenous bone
Description: Ridge augmentation by native collagen membrane and mix of anorganic bovine bone derived mineral with particulated autogenous bone chips (ratio 1:1).
Study: NCT03130101

Intervention type: OTHER
Group type: OTHER
Intervention: Change in their basal insulin rate
Description: Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Change in their basal insulin rate
Description: Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Change in their basal insulin rate
Description: Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.
Study: NCT01668927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Study: NCT03852615

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3 month post operation blood sample for AMH
Description: Additional blood sampling that will include a single tube containing 3 cc of blood for analysis of AMH will be taken three month from operation.
Study: NCT01300780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
Study: NCT00459407

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mass spectrometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high performance liquid chromatography
Description: Correlative studies
Study: NCT00433745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WT1 Peptide Vaccine
Description: WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
Study: NCT01300780

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 1 - Control Group will receive two doses of placebo tablet administered a every 8 hours,
Study: NCT00128219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS III-TT
Description: 50 mcg GBS Type III capsular polysaccharide conjugated to 32 mcg of tetanus toxoid. A single dose of vaccine administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus and diptheria toxoids vaccine
Description: Td vaccine is a sterile solution of alum-precipitated toxoids in isotonic sodium chloride solution. A single dose of vaccine will be administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml. Each 0.5 ml dose is formulated to contain 5 Lf (flocculation units) of tetanus toxoid and 2 Lf of diphtheria toxoid.
Study: NCT00674908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shan 5
Description: Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
Study: NCT03852615

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3 month post operation blood sample for AMH
Description: Additional blood sampling that will include a single tube containing 3 cc of blood for analysis of AMH will be taken three month from operation.
Study: NCT03911271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% atropine and 0.01% atropine
Description: 0.1% atropine loading dose for 6 months followed by 0.01% atropine for 18 months
Study: NCT02346487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/RTV pellets and AZT/3TC or ABC/3TC
Description: Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:~* Between 3 and 5.9kg: 2 capsules twice a day~* Between 6 and 9.9kg: 3 capsules twice a day~* Between 10 and 13.9kg: 4 capsules twice a day~* Between 14 and 19.9kg: 5 capsules twice a day~* Between 20 and 24.9kg: 6 capsules twice a day~Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:~* Between 3 and 5.9kg: 1 tablet twice a day~* Between 6 and 9.9kg: 1.5 tablets twice a day~* Between 10 and 13.9kg: 2 tablets twice a day~* Between 14 and 19.9kg: 2.5 tablets twice a day~* Between 20 and 24.9kg: 3 tablets twice a day
Study: NCT03911271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Description: 0.01% atropine for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: Placebo for 24 months
Study: NCT03389100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MK6240 injection
Description: Intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
Study: NCT02506439

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 mcg Vitamin D3
Description: Once daily, 10mcg (400IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
Study: NCT01668927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Study: NCT02506439

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 mcg Vitamin D3
Description: Once daily, 20mcg (800IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, placebo capsule containing 0mcg (0IU) of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
Study: NCT04739345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: 400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline
Description: 400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health
Study: NCT01668927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Study: NCT00465712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transabdominal amnioinfusion
Description: transabdominal amnioinfusion performed 4 to 24 hours before the second trial of external cephalic version
Study: NCT02419755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat should be taken orally (PO) with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat should be taken orally (PO) with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given by intravenous (IV) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given by intravenous (IV) injection.
Study: NCT02952066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial biopsy
Description: Bronchial tissue taken during biopsy
Study: NCT02438436

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: simo decoction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gum chewing
Study: NCT01795469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoex compression garment
Description: 5-strap compression of abdomen, thighs and legs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoex compression garment
Description: 5-strap compression of abdomen, thighs and legs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoex compression garment
Description: 5-strap compression of abdomen, thighs and legs
Study: NCT01376739

Intervention type: DRUG
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Description: Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
Study: NCT01868087

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Boost Plus®
Study: NCT01260311

Intervention type: DRUG
Intervention: Fesoterodine
Description: Any dose of Fesoterodine
Study: NCT01868087

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact Advanced Recovery®
Study: NCT02278185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate
Description: Given SC or IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin acetate
Description: Given SC or IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: histrelin acetate
Description: Given SC or IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triptorelin
Description: Given SC or IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: degarelix
Description: Given SC or IM
Study: NCT00722540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
Study: NCT02419755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given by intravenous (IV) injection.
Study: NCT00722540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study: NCT01073748

Intervention type: DRUG
Group type: OTHER
Intervention: paracetamol
Description: single dose of paracetamol 15mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: single dose of paracetamol 15mg/kg.
Study: NCT01873664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jaw-tapping
Description: to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.
Study: NCT01818557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood glucose testing
Description: Patients will be assigned either to blood glucose monitoring done every day (during a fasting state and 2 hours after breakfast, lunch and dinner) continued throughout gestation or to blood glucose monitoring done every other day with the same timeframes outlined above.
Study: NCT00590083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL administration
Description: Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.~One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2.
Study: NCT01946048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Procedure: Selected patients were randomly divided into a cell therapy group and a control group.~Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million.
Study: NCT01724307

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostimulation of stellate ganglion
Description: An electrical nuerostimulation of the stellate ganglion up to 60 minutes
Study: NCT00436215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 5 mg/kg intravenous (IV) every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
Study: NCT01647880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verum arm receiving Gilenya®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator receiving Extavia®
Study: NCT02704000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting program (Jamaica curriculum)
Description: Agents will deliver bi-weekly home-visits following the curriculum developed for the Jamaica intervention study by Susan Walker and colleagues. This curriculum foresees age-appropriate tasks assigned to the caregiver during each visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting program (Jamaica curriculum)
Description: Agents will deliver bi-weekly home-visits following the curriculum developed for the Jamaica intervention study by Susan Walker and colleagues. This curriculum foresees age-appropriate tasks assigned to the caregiver during each visit.
Study: NCT02777190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
Study: NCT00707304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talactoferrin
Description: Oral, 1.5 grams twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, twice per day
Study: NCT02708368

Intervention type: OTHER
Intervention: blood withdrawal
Description: 3 times

Intervention type: OTHER
Intervention: blood withdrawal
Description: 3 times
Study: NCT02349477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: gaba potentiating medication
Study: NCT01668927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Study: NCT00687232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4818
Description: Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02169193

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-Rhenium Sulfide Nanocolloid
Description: 12 MBq of NanoCis added to 500 ml of enteral feeding
Study: NCT02958189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tweet4Wellness
Description: A daily, behavior change theory-based intervention message is sent to a private, 25-person online Twitter-support group to prompt peer-to-peer discussion. Participants receive individual text messages to encourage group participation (e.g. 'thank you for participating' or 'please participate tomorrow'). Participants also receive weekly individual messages giving them daily step goals for the week based on their previous week's daily step average, recorded from Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: A Fitbit is provided to the group which tracks participants' daily steps.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: A Fitbit is provided to the group which tracks participants' daily steps.
Study: NCT02419755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given by intravenous (IV) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
Study: NCT01447056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMP specific T cells
Description: Three dose levels will be evaluated:~Dose Level 1: 2×10\^7 cells/m2; Dose Level 2: 1×10\^8 cells/m2; Dose Level 3: 2×10\^8 cells/m2~If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection.